Dr. Ledermann on the Results of the ARIEL3 Trial in Ovarian Cancer

Jonathan Ledermann, MD
Published: Wednesday, Nov 08, 2017



Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Results of ARIEL3 showed that there was a significant improvement in progression-free survival with maintenance rucaparib in the BRCA-mutant population, the homologous recombination deficient (HRD) cohort, and the all-comers cohort.
 


Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Results of ARIEL3 showed that there was a significant improvement in progression-free survival with maintenance rucaparib in the BRCA-mutant population, the homologous recombination deficient (HRD) cohort, and the all-comers cohort.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x